Cabotegravir

CAS No. 1051375-10-0

Cabotegravir ( S/GSK1265744;GSK 744; Cabotegravir )

Catalog No. M17126 CAS No. 1051375-10-0

Cabotegravir (GSK744, GSK1265744) is a long-acting HIV integrase inhibitor and inhibits the HIV-1 integrase catalyzed strand transfer reaction (IC50: 3.0 nM).

Purity : 98%

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
10MG 41 In Stock
25MG 80 In Stock
50MG 142 In Stock
100MG 178 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Cabotegravir
  • Note
    Research use only, not for human use.
  • Brief Description
    Cabotegravir (GSK744, GSK1265744) is a long-acting HIV integrase inhibitor and inhibits the HIV-1 integrase catalyzed strand transfer reaction (IC50: 3.0 nM).
  • Description
    Cabotegravir, also known as S/GSK1265744 or GSK744, is potent HIV integrase inhibitor under development for the treatment of HIV infection. Cabotegravir has a carbamoyl pyridone structure similar to dolutegravir.
  • Synonyms
    S/GSK1265744;GSK 744; Cabotegravir
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    HIV integrase
  • Research Area
    Infection
  • Indication
    ——

Chemical Information

  • CAS Number
    1051375-10-0
  • Formula Weight
    405.35
  • Molecular Formula
    C19H17F2N3O5
  • Purity
    98%
  • Solubility
    DMSO : 12.67 mg/mL 31.26 mM;
  • SMILES
    C[C@H]1CO[C@H]2N1C(=O)c1c(c(=O)c(cn1C2)C(=O)NCc1c(cc(cc1)F)F)O
  • Chemical Name
    (3S,11aR)-N-(2,4-difluorobenzyl)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Yoshinaga T, et al. Antimicrob Agents ChemOthers. 2015, 59(1), 397-406.
molnova catalog
related products
  • AS-604850

    AS-604850 is a specific and ATP-competitive PI3Kγ inhibitor (IC50: 250 nM), 18-fold more selective for PI3Kγ than PI3Kα, and over 80-fold selectivity for PI3Kγ than PI3Kδ/β.

  • Isogambogenic acid

    Isogambogenic acid inhibits angiogenesis and may be a viable drug candidate in anti-angiogenesis therapy.

  • Ginsenoside Rk3

    Ginsenoside Rk3 and Rh4 could have a role in treating inflammatory diseases.